INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449 March 23, 2009				Attorney Docket No. 056291-5296		Application No. 19/586,954	
				Applicants: David Michael ANDREWS et al.			
				Filing Date: July 25, 2006		Group Art Unit: 1624	
			U.S. PA	TENT DOCUMENTS			
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
						-	
-					-	+	
						-	
						1	
			EODEICN	PATENT DOCUMENTS	····		
1		Document No.	Date	Country	Class	Sub-Class	Translation
	1.	WO 2004/005282	January 15, 2004			20 0.233	
	2.	WO 2005/068452	July 28, 2005	WIPO			
	3.	WO 2007/040436	April 12, 2007	WIPO			
	4.	WO 2008/002244	January 3, 2008	WIPO			
	5.	WO 2008/002245	January 3, 2008	WIPO			
		OTHER DO	CUMENTS (Includ	ling Author, Title, Date, P	ertinent Pa	ges, etc.)	
	6.			potent and selective class			
		through structure-based hybridisation" Bioorganic & Medicinal Chemistry Letters 13(18):3021-3026 (2003).					
		Byth et al. "Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-depe					
		kinase inhibitors' Bioorganic & Medicinal Chemistry Letters 14(9): 2245-2248 (2004). Byth et al. "Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors" Bio					
	٥.	& Medicinal Chemistry	Letters 14(9): 2249	-2252 (2004).	-		-
	9.			3, a novel selective imidaze	o[1,2-a]pyri	dine cyclin-de	ependent kinase
		inhibitor" Molecular Ca	ancer Therapeutics 5	(3):655-664 (2006).			